Summary
Plasma concentrations of pancuronium bromide have been studied in seven surgical patients following a 6 mg intravenous bolus injection of the drug for neuromuscular blockade. Concurrently, evoked muscle twitch response was monitored for each patient as a measure of the pharmacodynamic effect of the drug. The plasma decay curve for pancuronium was found to be biphasic and after rigorous statistical analysis the data were interpreted according to a 2-compartment open model. The half-life of the β-phase varied between 89.5 and 161.5 min. The apparent volume of distribution of the central compartment ranged from 62.9 to 145.5 ml/kg and the plasma clearance from 57.6 to 187.3 ml/min. At the first sign of recovery from neuro-muscular blockade the mean pancuronium plasma level was found to be 0.218 mcg/ml. The mean duration of action as measured from time of onset of paralysis to 20% recovery was 83.4 min with the plasma level at 20% being 0.169 mcg/ml corresponding to 45.4% of dose remaining to be eliminated from the body.
Similar content being viewed by others
References
Agoston, S., Vermeer, G.A., Kersten, U.W. Meijer, D.K.F.: The fate of pancuronium bromide in man. Acta anaesth. scand.17 267–275 (1973)
Buzello, W.: Der Stoffwechsel von Pancuronium beim Menschen. Anaesthesist24 13–18 (1975)
Gibaldi, M., Levy, G., Weintraub, H.: Drug distribution and pharmacologic effects. Clin. Pharmacol. Ther.12 734–742 (1971)
McLeod, K., Watson, M.J., Rawlins, M.D.: Plasma concentrations of pancuronium bromide (Pavulon) in patients with normal and impaired renal function. Brit. J. Anaesth.47 902–903 (1975)
Kersten, U.W., Meijer, D.K.F., Agoston, S.: Fluorimetric and chromatographic determination of pancuronium bromide and its metabolites in biological materials. Clin. chim. Acta44 59–66 (1973)
Katz, R.L.: Comparison of electrical and mechanical recording of spontaneous and evoked muscle activity. Anesthesiology26 204–211 (1965)
Metzler, C.M.: Nonlin; a computer program for parameter estimation in nonlinear situations. Kalamazoo, Mich.: The Upjohn Company, Nov. 25, 1969, Technical Report No. 7292/69/7292/005.
Boxenbaum, H.G., Riegelman, S., Elashoff, R.M.: Statistical estimations in pharmacokinetics. J. Pharmacokin. Biopharm.2 123–148 (1974)
Gibaldi, M., Levy, G., Hayton, W.: Kinetics of the elimination and neuromuscular blocking effect of d-tubocurarine in man. Anesthesiology36 213–218 (1972)
Gibaldi, M., Levy, G., Hayton, W.: Tubocurarine and renal failure. Brit. J. Anaesth.44 163–165 (1972)
Miller, R.D., Stevens, W.C., Way, W.L.: The effect of renal failure and hyperkalemia on the duration of pancuronium neuromuscular blockade in man. Anesth. Analg. Curr. Res.52 661–665 (1974)
Kamvyssi-Dea, S., Papadimitriou, K., Dousaitou, P.: The use of pancuronium bromide in operations for renal insufficiency. Brit. J. Anaesth.44 1217–1218 (1972)
Katz, R.L., Katz, G.J.: Clinical considerations in the use of muscle relaxants. In: Monographs in anaesthesiology Vol. 3. Muscle relaxants (ed. R.L. Katz), pp. 313–334. Amsterdam, London, New York: Excerpta Medica 1975
Fell, P.J., Stevens, M.T.: Pharmacokinetics — uses and abuses. Europ. J. Clin. Pharmacol.8 241–248 (1975)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Somogyi, A.A., Shanks, C.A. & Triggs, E.J. Clinical pharmacokinetics of pancuronium bromide. Eur J Clin Pharmacol 10, 367–372 (1976). https://doi.org/10.1007/BF00565627
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00565627